Becton Dickinson executive sells 75 BDX shares at $193.36 each
Becton Dickinson & Co. executive Michael Feld, who serves as EVP, CRO & President of Life Sciences, reported a small sale of company stock.
Rhea-AI Filing Summary
Becton Dickinson & Co. executive Michael Feld, who serves as EVP, CRO & President of Life Sciences, reported a small sale of company stock. On 12/01/2025, he sold 75 shares of Becton Dickinson common stock at a price of $193.36 per share. After this transaction, he beneficially owned 16,580 shares of Becton Dickinson common stock in direct ownership. The filing notes that this sale was made under a pre-arranged Rule 10b5-1 trading plan that Feld adopted on February 7, 2025, which is designed to allow insiders to sell shares according to a preset schedule.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 75 | $193.36 | $15K |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Becton Dickinson (BDX) report for Michael Feld?
Michael Feld, EVP, CRO & President of Life Sciences at Becton Dickinson & Co., reported selling 75 shares of Becton Dickinson common stock in a transaction dated 12/01/2025.
Was the Becton Dickinson (BDX) insider sale made under a Rule 10b5-1 plan?
Yes. The filing states that the reported transaction was made pursuant to a Rule 10b5-1 plan adopted by Michael Feld on February 7, 2025.
What is Michael Feld’s role at Becton Dickinson (BDX)?
Michael Feld is identified as an officer of Becton Dickinson & Co., serving as EVP, CRO & President of Life Sciences.
Is this Becton Dickinson (BDX) Form 4 filed by one or multiple reporting persons?
The Form 4 is indicated as being filed by one reporting person, covering the transactions of Michael Feld only.
AI-generated analysis. How Rhea-AI works. Not financial advice.